Editor's Choice | Page 95 of 113 | Links Medicus Content Curation & Alerts in Medicine

M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

7 Apr, 2022 | 09:55h | UTC

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

Bayesian SRMA of 3 RCTs showed a high prob (94-98.6%) that fluvoxamine is associated with reduced risk of hospitalization for outpatients with #COVID19, (RR 0.75). @DrEmilyMcD @DrToddLee @simonevigod @AngelaReiersen @boulware_dr https://t.co/ctMKzBDbzP

— JAMA Network Open (@JAMANetworkOpen) April 6, 2022

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter (thread – click for more)

#JustPublished!#ECDC and @EMA_News issue advice on fourth doses of mRNA #COVID19 vaccines.

Read the full joint statement: https://t.co/hBuOlrfKOD pic.twitter.com/aO5vSyYvTk

— ECDC (@ECDC_EU) April 6, 2022

Pragmatic RCT: In outpatients with Covid-19, the addition of pulse oximetry for monitoring did not improve outcomes compared to subjective assessments of dyspnea alone.

7 Apr, 2022 | 09:58h | UTC

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

Commentary on Twitter

A potential practice changer by @kit_delgadoMD et al in NEJM today.

At-home pulse oximeters did NOT improve outcomes.

Important to focus on things that help.

If these devices don't help, then we shouldn't routinely advise them.

Super interesting work.https://t.co/VDDyRLw7ba

— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 6, 2022

RCT: Among patients with complicated urinary tract infection, oral Tebipenem Pivoxil Hydrobromide was noninferior to intravenous Ertapenem and showed a similar safety profile.

7 Apr, 2022 | 09:53h | UTC

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

For complicated UTI or acute pyelonephritis, oral tebipenem pivoxil hydrobromide noninferior to IV ertapenem and has a similar safety profile. https://t.co/FRDMQOD0Pn pic.twitter.com/GFQz7SlciX

— NEJM (@NEJM) April 6, 2022

RCT: Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne Muscular Dystrophy.

7 Apr, 2022 | 08:53h | UTC

Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial – JAMA (free for a limited period)

RCT: Routine lung volume recruitment is not beneficial for boys with Duchenne muscular dystrophy.

Phase 2 RCT: Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy.

Research: Long-term effects of glucocorticoids in patients with Duchenne muscular dystrophy

Commentary on Twitter

In this randomized clinical trial of boys with Duchenne muscular dystrophy, treatment with daily #prednisone or daily #deflazacort resulted in significantly better outcomes compared with intermittent prednisone. https://t.co/rKjSrjVemR #AAN2022 pic.twitter.com/qPNV9KBOXv

— JAMA (@JAMA_current) April 5, 2022

Opinion: The medical algorithmic audit.

7 Apr, 2022 | 09:51h | UTC

The medical algorithmic audit – The Lancet Digital Health

Linked Article: Validation and algorithmic audit of a deep learning system for the detection of proximal femoral fractures in patients in the emergency department: a diagnostic accuracy study – The Lancet Digital Health

Commentary on Twitter

“without the ability to observe and learn from algorithmic errors, the risk is that it will continue to happen and there's no accountability for any harm that results"
NEW Editorial: 'Holding #ArtificialIntelligence to account'.https://t.co/Dg3OtJZZT9 pic.twitter.com/JQbrXbbNqy

— The Lancet Digital Health (@LancetDigitalH) April 6, 2022

Randomized, sham-controlled trial: Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs.

7 Apr, 2022 | 09:49h | UTC

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Three-year trial of SPYRAL HTN-ON MED shows blood pressure reductions – MedicalXpress

Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.

M-A: Renal denervation for hypertension is associated with a modest reduction in ambulatory blood pressure control (3.61 mm Hg reduction in ambulatory systolic BP and 1.85 mm Hg reduction in ambulatory diastolic BP).

#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.

Meta-Analysis: Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients with Hypertension

Commentary on Twitter

Renal denervation could provide an adjunctive treatment modality in the management of patients with #hypertension, suggests trial assessing long-term efficacy & safety in the presence of antihypertensive drugs: https://t.co/45ojbyhQp3 pic.twitter.com/eg6CXGDGCE

— The Lancet (@TheLancet) April 6, 2022

Perspective | Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

7 Apr, 2022 | 08:45h | UTC

Studying severe long COVID to understand post-infectious disorders beyond COVID-19 – Nature Medicine

Review: Post-acute COVID-19 syndrome.

ESCMID rapid guidelines for assessment and management of long COVID.

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

Commentary from the author on Twitter (thread – click for more)

1/ HGE (https://t.co/VMUVMAo1bJ) position paper on #LongCOVID #PACS . By focusing on the most severe patients, w severe organ damage/dysfunction following mild/moderate #COVID19 – we will search for genetic and immunological mechanisms of disease https://t.co/dZQPEoNkhl pic.twitter.com/tgblk7oFQG

— Petter Brodin (@BrodinPetter) April 5, 2022

Perspective | An equitable roadmap for ending the COVID-19 pandemic.

7 Apr, 2022 | 08:48h | UTC

An equitable roadmap for ending the COVID-19 pandemic – Nature Medicine

Commentary on Twitter

A Comment article in @NatureMedicine argues that the COVID-19 pandemic will end only with a renewed focus on equitable distribution of vaccines and therapeutics, responsive public health plans, and policies to protect the vulnerable. https://t.co/2cZShdqnY3

— Nature Portfolio (@NaturePortfolio) April 6, 2022

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

6 Apr, 2022 | 10:59h | UTC

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter

Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j

— Eric Topol (@EricTopol) April 5, 2022

Retrospective cohort study: Waning COVID-19 vaccine effectiveness for Pfizer and CoronaVac in Malaysia.

6 Apr, 2022 | 10:57h | UTC

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study – International Journal of Infectious Diseases

Commentary on Twitter

@ICR_NIH RECoVam's
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia in IJID.https://t.co/QwNSRQBKOq

• Against infections, both wane after 3-5 months
• Against ICU admission, CoronaVac wane
• Against death, both retain considerable effectiveness

— Dr Kalai Peariasamy (@drkalai61) March 22, 2022

Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

6 Apr, 2022 | 10:52h | UTC

Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US – JAMA Pediatrics

Commentary: Omicron ‘less severe’ than Delta for children ages 4 and younger, study suggests – Case Western Reserve University

Commentary on Twitter

In this cohort study, the incidence rate of #SARSCoV2 infection with Omicron variant was 6 to 8 times that of Delta variant in children younger than 5 years, but severe clinical outcomes were less frequent than with Delta variant. https://t.co/UKiMEznXtX

— JAMA Pediatrics (@JAMAPediatrics) April 1, 2022

M-A: Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives.

6 Apr, 2022 | 10:55h | UTC

Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis – Journal of Thrombosis and Haemostasis

RCT: Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage.

6 Apr, 2022 | 10:47h | UTC

Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients – Journal of Neurosurgery

RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.

6 Apr, 2022 | 10:51h | UTC

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)

FDA approves first injectable treatment for HIV pre-exposure prevention.

RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.

Review and M-A: pulmonary rehabilitation for Post-Covid.

6 Apr, 2022 | 10:42h | UTC

Study 1: The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature – Respiratory Medicine

Study 2: Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis – Frontiers in Medicine

Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019.

6 Apr, 2022 | 10:49h | UTC

Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study – The Lancet Public Health

News Release: Global disparities persist in opioid painkiller access – University College London

Invited Commentary: Closing the global pain divide: balancing access and excess – The Lancet Public Health

Commentary on Twitter (article and images under a Creative Commons Attribution (CC BY 4.0 license)

Just Out @TheLancetPH 🚨
Global #opioids consumption increased from 2015 to 2019‼️#Disparities in opioid💊consumption remained, indicating potential inadequate access to essential pain relief in countries with low consumption🌐https://t.co/bkcdgLy3ZP pic.twitter.com/RUGl1gbiTw

— Gil Morgan, MD (@weoncologists) April 1, 2022

RCT: Oral Roxadustat vs. Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis.

6 Apr, 2022 | 10:45h | UTC

Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study – Journal of the American Society of Nephrology

Randomized Trials: Evaluation of New Treatment for Anemia of Chronic Kidney

RCT: Efficacy and safety of Daprodustat (oral drug) for treating anemia of chronic kidney disease in incident dialysis patients.

RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.

RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.

Cohort study and updated meta-analysis: greater dietary cholesterol and egg consumption linked to increased risk of overall and CVD mortality.

6 Apr, 2022 | 10:41h | UTC

Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality, and Systematic Review and Updated Meta-Analysis – Circulation

Billions of people still breathe unhealthy air: new WHO data.

5 Apr, 2022 | 09:59h | UTC

News Release: Billions of people still breathe unhealthy air: new WHO data – World Health Organization

Report: WHO Air quality Database 2022

Commentaries:

South-East Asia, Africa and Middle East are World’s Air Pollution Hot Spots in WHO’s Largest-Ever Data Release – Health Policy Watch

WHO says 99% of world’s population breathes poor-quality air – Associated Press

Commentary on Twitter (thread – click for more)

Shocking!
99% – or almost the entire world's population breathes air with unhealthy levels of fine particulate matter & nitrogen dioxide, and threatens their health.
More: https://t.co/Llaj2wHk0V #HealthierTomorrow pic.twitter.com/QlHUP4iyS4

— World Health Organization (WHO) (@WHO) April 4, 2022